<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB/A No. 1
[xx] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended September 30, 1996
------------------
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
--------------- --------------
Commission File Number: 33-14042-NY
-----------------------------------
NeuroCorp. (formerly Tamarac Ventures, Ltd.)
- -------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Nevada 87-0446395
- -------------------------------- -----------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
150 White Plains Road, Tarrytown, New York 10591
- -------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(914) 631-3315
- -------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
- -------------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
Check whether the issuer (1) has filed all reports required to be filed by
section 13 or 15 (d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes [xx] No [ ]
APPLICABLE ONLY TO CORPORATE ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS
Check whether the registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court.
Yes [ ] No [ ]
APPLICABLE ONLY TO CORPORATE ISSUERS
State the number of shares outstanding of each of the issuer's classes of common
equity as of the latest practicable date: 7,173,807 Shares as of September 30,
1996.
<PAGE>
FORM 10-QSB
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
NeuroCorp. Ltd.
-----------------------------------
(Registrant)
November 20, 1996 /s/ Turan M. Itil, M.D.
- ----------------- -----------------------------------
Date By: Turan M. Itil, M.D.
Chief Executive Officer and
Director
<PAGE>
FORM 10-QSB/A No. 1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
NeuroCorp. Ltd.
-----------------------------------
(Registrant)
December 23, 1996 /s/ Turan M. Itil, M.D.
- ----------------- -----------------------------------
Date By: Turan M. Itil, M.D.
Chief Executive Officer and
Director
<PAGE>
OPTON HANDLER GOTTLIEB FEILER & KATZ
52 VANDERBILT AVENUE
NEW YORK, NEW YORK 10017
TELEPHONE (212) 599-1744
TELEPHONE (212) 972-2219
DECEMBER 23, 1996
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Re: NEUROCORP, LTD.
FILE NO. 33-14042-144
Dear Ladies and Gentlemen:
Enclosed please find Amendment No. 1 to Form 10-QSB for the
quarterly period ended September 30, 1996. This Amendment relates only to the
Signature Page of the Form 10-QSB which was inadvertently omitted from the
original filing.
Very truly yours,
Peter Landau
PL: mdy
Enclosure
